Fujirebio Lumipulse pTau 217 Plasma Controls recalled for inaccurate Alzheimer's disease test results
Stop using Fujirebio pTau 217 Plasma Controls
Fujirebio Diagnostics is recalling Lumipulse pTau 217 Plasma Controls (Model 81558) used in laboratory testing for Alzheimer's disease markers. The controls may produce falsely elevated results, leading labs to incorrectly classify patients as having Alzheimer's disease or requiring additional testing.
- If your laboratory uses this product, stop using affected lot numbers D6C6092U, D6C6092U1, and D6C6123U immediately.
- Contact Fujirebio Diagnostics for instructions on returning the product and obtaining replacements.
- Review any patient test results from affected lot numbers with your healthcare provider or laboratory director.
Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an incorrect classification of a patient as having amyloid pathology associated with Alzheimer s disease (positive result) and/or requiring more clinical testing of that patient (indeterminate result).
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-1304-2026Don't want to check this manually?
We email you a Sunday digest of new federal recalls relevant to parents — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.
Get the Sunday Brief